Resource Library
New to the Resource Library?
Learn how to navigate, search, and use our resources effectively.
Neuropsychological functioning of patients with major depression or bipolar disorder comorbid to substance use disorders: A systematic review
The co-occurrence of substance use disorders and mental health conditions, called dual disorders, is common and linked to worse health outcomes. Major depression and bipolar disorder are the most frequently reported co-occurring conditions.
Default Mode Network Modulation by Psychedelics: A Systematic Review
Psychedelics, known as "mind-manifesting" agents, may alter consciousness by affecting the brain's Default Mode Network (DMN). These effects show promise for treating various neuropsychiatric conditions.
Psychedelics reopen the social reward learning critical period
Research shows that various psychedelics can reopen a "critical period" in the brain, enhancing social reward learning in adulthood. This suggests a common mechanism that may contribute to their therapeutic potential.
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
This study explored challenging psychedelic experiences in a representative US adult sample. It examined how psychological traits, medication use, and environment relate to these experiences.
Case analysis of long-term negative psychological responses to psychedelics
This study focuses exclusively on negative psychological responses to psychedelics that last longer than 72 hours. It aims to understand why these long-term negative mental health issues occur, given growing general use.
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Researchers discovered that psychedelics like LSD and psilocybin directly bind to a protein called TrkB with high affinity.
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
This study found that certain compounds, including psychedelics, can rapidly promote new brain cell growth and have antidepressant-like effects. This growth appears linked to their ability to activate serotonin receptors inside cells.
Psychedelics: Threshold of a Therapeutic Revolution
This issue updates research on psychedelic drugs, showing remarkable progress in basic and clinical studies since 2018. It details current policies, ethics, and legal considerations for their potential use as mainstream therapies.
Cocaine or Methamphetamine Use During Young Adulthood Following Stimulant Use for Attention-Deficit/Hyperactivity Disorder During Adolescence
Adolescents prescribed stimulants for ADHD did not show an increased risk of later illicit stimulant use. However, adolescents misusing prescription stimulants had a higher risk of later using cocaine or methamphetamine.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
MDMA-assisted therapy significantly reduced PTSD symptoms and functional impairment in a diverse population with moderate to severe PTSD. The treatment was well-tolerated.
Neurocognitive Recovery in Abstinent Patients with Alcohol Use Disorder: A Scoping Review for Associated Factors
Chronic alcohol use disorder often leads to cognitive impairments that hinder treatment success. While abstinence can help, recovery varies, and more longitudinal research is needed to understand influencing factors beyond just abstinence.
Pathways to the persistence of drug use despite its adverse consequences
This article identifies three pathways—cognitive, motivational, and behavioral—that explain why individuals continue drug use despite negative consequences. These pathways can operate differently within an individual over time.
The genetically informed neurobiology of addiction (GINA) model
Addiction is now understood as a neurobiological state influenced by genetics and environment. A new model, GINA, explains how genetic risk and substance-induced brain changes contribute to addiction's development.
Ruan v. United States
The Supreme Court ruled that to convict a doctor under the Controlled Substances Act, the government must prove they knowingly or intentionally acted without authorization, once authorized prescribing is shown.
People v. Pacheco
The court denied mental health diversion for Pacheco, who started a fire while using meth, due to public safety concerns, despite his schizophrenia and treatment plans. This denial was upheld.